salix

UBS has initiated coverage for Salix Pharmaceuticals (NASDAQ: SLXP) at Neutral with a $45 price target.

Re: Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), it is reported by Piper Jaffray that "Though there is lingering anxiety on the Street regarding the potential for an advisory committee meeting to discuss the Xifaxan NDA filing in non-constipation irritable bowel syndrome (IBS), we continue to...